{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:46:55Z","timestamp":1791269215164,"version":"4.1.0"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA062924"],"award-info":[{"award-number":["P50 CA062924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA197296"],"award-info":[{"award-number":["R01 CA197296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA247886"],"award-info":[{"award-number":["P01 CA247886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA169702"],"award-info":[{"award-number":["R01 CA169702"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["882103400"],"award-info":[{"award-number":["882103400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.canlet.2025.217616","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:43:01Z","timestamp":1741239781000},"page":"217616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Clinical development of immuno-oncology therapeutics"],"prefix":"10.1016","volume":"617","author":[{"given":"Jianxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"qiang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-2541","authenticated-orcid":false,"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.canlet.2025.217616_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ucl.2020.07.001","article-title":"His hypothesis, his toxin, and the birth of immunotherapy","volume":"47","author":"Loughlin","year":"2020","journal-title":"Urol. Clin. North Am."},{"issue":"2","key":"10.1016\/j.canlet.2025.217616_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217616_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz","year":"1992","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib5","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2025.217616_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.canlet.2025.217616_bib7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217616_bib8","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"43","key":"10.1016\/j.canlet.2025.217616_bib9","first-page":"118","article-title":"Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response","author":"Gangaev","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-024-01956-6","article-title":"Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison","volume":"23","author":"Cheng","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2025.217616_bib11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib14","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217616_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216871","article-title":"The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors","volume":"591","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.canlet.2025.217616_bib16","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.ymthe.2024.05.039","article-title":"Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies","volume":"32","author":"Al Hadidi","year":"2024","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.canlet.2025.217616_bib17","article-title":"The role of CAR T-cell therapy in relapsed\/refractory adult B-all","volume":"22","author":"Othman","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"24","key":"10.1016\/j.canlet.2025.217616_bib18","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2024025828","article-title":"T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2025.217616_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","author":"Lopez de Rodas","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217281","article-title":"Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer","volume":"605","author":"Plaugher","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib24","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217616_bib25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.canlet.2025.217616_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217616_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216634","article-title":"Oncolytic virus-based combination therapy in breast cancer","volume":"585","author":"Bahreyni","year":"2024","journal-title":"Cancer Lett."},{"issue":"5\u20136","key":"10.1016\/j.canlet.2025.217616_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000334863","article-title":"Noncutaneous melanoma have distinct features from each other and cutaneous melanoma","volume":"81","author":"Tas","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2025.217616_bib30","unstructured":"SEER Cancer Stat Facts: Melanoma of the Skin. National Cancer Institute Bethesda, MD."},{"issue":"5","key":"10.1016\/j.canlet.2025.217616_bib31","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","article-title":"Immune checkpoint inhibitors to treat cutaneous malignancies","volume":"83","author":"Barrios","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"26","key":"10.1016\/j.canlet.2025.217616_bib32","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib33","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.canlet.2025.217616_bib34","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.217616_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canlet.2025.217616_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217616_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217616_bib39","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217616_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J. Immunother Cancer"},{"issue":"25","key":"10.1016\/j.canlet.2025.217616_bib43","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217616_bib44","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217616_bib45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ccm.2020.02.010","article-title":"Advances in the treatment of non-small cell lung cancer: immunotherapy","volume":"41","author":"Patel","year":"2020","journal-title":"Clin. Chest Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.217616_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.canlet.2025.217616_bib47","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"10.1016\/j.canlet.2025.217616_bib48","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10030","key":"10.1016\/j.canlet.2025.217616_bib49","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"10066","key":"10.1016\/j.canlet.2025.217616_bib50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.canlet.2025.217616_bib51","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.canlet.2025.217616_bib52","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10183","key":"10.1016\/j.canlet.2025.217616_bib53","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.canlet.2025.217616_bib54","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10274","key":"10.1016\/j.canlet.2025.217616_bib55","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib56","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2025.217616_bib57","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.canlet.2025.217616_bib58","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib59","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.canlet.2025.217616_bib60","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.217616_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.canlet.2025.217616_bib62","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.canlet.2025.217616_bib63","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10308","key":"10.1016\/j.canlet.2025.217616_bib64","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.canlet.2025.217616_bib65","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2025.217616_bib66","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib67","volume":"11\/08","author":"Squibb","year":"2021"},{"issue":"13 Supplement","key":"10.1016\/j.canlet.2025.217616_bib68","article-title":"Abstract CT003: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial","volume":"81","author":"Forde","year":"2021","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2025.217616_bib69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.canlet.2025.217616_bib70","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.canlet.2025.217616_bib71","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2003.12.006","article-title":"Small cell lung cancer: state of the art and future perspectives","volume":"45","author":"Stupp","year":"2004","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217616_bib73","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"23","key":"10.1016\/j.canlet.2025.217616_bib75","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.canlet.2025.217616_bib76","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.canlet.2025.217616_bib77","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10265","key":"10.1016\/j.canlet.2025.217616_bib79","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib80","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217616_bib81","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217616_bib82","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol."},{"issue":"10294","key":"10.1016\/j.canlet.2025.217616_bib83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.canlet.2025.217616_bib84","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1200\/JCO.2021.39.15_suppl.4013","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G\/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study","volume":"39","author":"Janjigian","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217616_bib85","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol."},{"issue":"35","key":"10.1016\/j.canlet.2025.217616_bib86","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib87","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.canlet.2025.217616_bib88","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib89","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib90","unstructured":"SEER Cancer Stat Facts: Colorectal Cancer. National Cancer Institute Bethesda, MD."},{"issue":"6","key":"10.1016\/j.canlet.2025.217616_bib91","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib92","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10088","key":"10.1016\/j.canlet.2025.217616_bib93","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib94","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.canlet.2025.217616_bib95","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.217616_bib96","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol. : Offic. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib97","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"16","key":"10.1016\/j.canlet.2025.217616_bib98","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.7150\/jca.22532","article-title":"PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer","volume":"9","author":"Meng","year":"2018","journal-title":"J. Cancer"},{"issue":"12","key":"10.1016\/j.canlet.2025.217616_bib99","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod. Pathol."},{"issue":"17","key":"10.1016\/j.canlet.2025.217616_bib100","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib101","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib102","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib103","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0090-8258(21)00657-0","article-title":"A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer","volume":"162","author":"Makker","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib104","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol. : Offic. J. European Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J. Immunother Cancer"},{"issue":"19","key":"10.1016\/j.canlet.2025.217616_bib106","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.canlet.2025.217616_bib107","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.canlet.2025.217616_bib108","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.canlet.2025.217616_bib109","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib110","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.canlet.2025.217616_bib111","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.canlet.2025.217616_bib112","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11934-018-0851-7","article-title":"Immunotherapy for urothelial carcinoma: current evidence and future directions","volume":"19","author":"Tripathi","year":"2018","journal-title":"Curr. Urol. Rep."},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib113","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib114","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.canlet.2025.217616_bib115","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217616_bib116","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib117","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib118","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib119","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.canlet.2025.217616_bib120","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.canlet.2025.217616_bib121","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib122","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.canlet.2025.217616_bib123","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib124","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.canlet.2025.217616_bib125","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9323","key":"10.1016\/j.canlet.2025.217616_bib126","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib127","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.canlet.2025.217616_bib128","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217616_bib129","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"issue":"34","key":"10.1016\/j.canlet.2025.217616_bib130","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217616_bib131","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr. Hematol Malig. Rep."},{"issue":"6","key":"10.1016\/j.canlet.2025.217616_bib132","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217616_bib133","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10299","key":"10.1016\/j.canlet.2025.217616_bib134","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.canlet.2025.217616_bib135","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib136","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10254","key":"10.1016\/j.canlet.2025.217616_bib137","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.217616_bib138","series-title":"FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma","year":"2021"},{"issue":"14","key":"10.1016\/j.canlet.2025.217616_bib139","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.217616_bib140","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10435","key":"10.1016\/j.canlet.2025.217616_bib141","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.canlet.2025.217616_bib142","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. immunotherapy cancer"},{"issue":"16","key":"10.1016\/j.canlet.2025.217616_bib143","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.canlet.2025.217616_bib144","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib145","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.canlet.2025.217616_bib146","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217616_bib147","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.canlet.2025.217616_bib148","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.canlet.2025.217616_bib149","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.canlet.2025.217616_bib150","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: jacc: CardioOncology primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib151","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J. Urol."},{"issue":"19","key":"10.1016\/j.canlet.2025.217616_bib152","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217616_bib153","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.canlet.2025.217616_bib154","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1158\/0008-5472.CAN-23-2846","article-title":"ARID1A-Deficient tumors acquire immunogenic neoantigens during the development of resistance to targeted therapy","volume":"84","author":"Okada","year":"2024","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib155","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1039\/D3CS00162H","article-title":"Advancing nanotechnology for neoantigen-based cancer theranostics","volume":"53","author":"Zou","year":"2024","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"issue":"10427","key":"10.1016\/j.canlet.2025.217616_bib157","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.canlet.2025.217616_bib158","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.canlet.2025.217616_bib159","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions","volume":"562","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib161","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217616_bib162","article-title":"Neutrophils in cancer drug resistance: roles and therapeutic opportunities","volume":"611","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217616_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217272","article-title":"Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma","volume":"604","author":"Huang","year":"2024","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2025.217616_bib164","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib165","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017745012","article-title":"Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)","volume":"10","author":"Moya-Horno","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"17","key":"10.1016\/j.canlet.2025.217616_bib166","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","article-title":"A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1\/PD-L1","volume":"27","author":"Weiss","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.217616_bib167","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/OP.20.00996","article-title":"Immunotherapy management in special cancer patient populations","volume":"17","author":"Ramnaraign","year":"2021","journal-title":"JCO Oncol Pract."},{"issue":"10","key":"10.1016\/j.canlet.2025.217616_bib168","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1158\/2767-9764.CRC-24-0439","article-title":"Peripheral blood IFN responses to toll-like receptor 1\/2 signaling associate with longer survival in men with metastatic prostate cancer treated with sipuleucel-T","volume":"4","author":"Brown","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2025.217616_bib169","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.35309","article-title":"Estrogen, estrogen receptor and the tumor microenvironment of NSCLC","author":"Diao","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2025.217616_bib170","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2326-6066.CIR-23-0121","article-title":"Considerations and approaches for cancer immunotherapy in the aging host","volume":"11","author":"Ontiveros","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217616_bib171","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1038\/s41467-022-31055-3","article-title":"Recurrent somatic mutations as predictors of immunotherapy response","volume":"13","author":"Gajic","year":"2022","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.canlet.2025.217616_bib172","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217616_bib173","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","article-title":"Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients","volume":"65","author":"Duffy","year":"2019","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.canlet.2025.217616_bib174","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217616_bib175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.217616_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217073","article-title":"Peripheral CD8(+)PD-1(+) T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer","volume":"597","author":"Guo","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217616_bib177","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol. Ther. Oncolytics."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525001806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525001806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:06:48Z","timestamp":1777550808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":177,"alternative-id":["S0304383525001806"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217616","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical development of immuno-oncology therapeutics","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217616"}}